Zurück geht es hier Grüezi! Sie wurden auf finanzen.ch, unser Portal für Schweizer Anleger, weitergeleitet.  Zurück geht es hier.
09.05.2025 15:30:00

Cytel Partners with Nested Knowledge to Power the Next Generation of AI-Enhanced LiveSLR® for HEOR and HTA

Cambridge, MA and St. Paul, MN, May 09, 2025 (GLOBE NEWSWIRE) -- Cytel, a global leader in evidence generation and data-driven decision-making, today announced a partnership with Nested Knowledge, a pioneer in AI-powered systematic literature review technology. The partnership pairs Cytel’s proprietary LiveSLR® software with Nested Knowledge’s advanced AI platform, creating an advanced, fully auditable living evidence platform available for Health Economics and Outcomes Research (HEOR) and Health Technology Assessment (HTA).

This collaboration enables Cytel’s unique LiveSLR® platform to be powered by Nested Knowledge – an offering that combines Cytel’s industry-leading SLR methodology and domain expertise with cutting-edge AI-driven automation. Unique in the field of evidence evaluation and synthesis, Cytel will deliver a distinct advantage through its expert-led approach to search strategy design, expansive database access, and superior evidence reporting capabilities.

"Cytel is excited to work with Nested Knowledge to ensure our clients can realize the advantages of our LiveSLR® and Nested Knowledge best-in-class offerings for their evidence and health economics needs” noted Wyatt Gotbetter, Global Head of Cytel Evidence, Value and Access. "With LiveSLR® and Nested Knowledge software, our customers can feel confident we’re employing the standard and get access to a set of differentiated deliverables to interact with their HEOR living evidence.”

As the SLR market grows more competitive – Cytel stands apart by offering:

  • Best-in-class AI-enabled screening and extraction
  • Automated generation of unlimited reports filtered by PICO criteria, ideal for global-to-local adaptation
  • Superior search strategies based on broad database access and deep domain knowledge
  • Industry-leading analytic and reporting capabilities, tailored to HTA and reimbursement decision-makers

Keith Kallmes, President of Nested Knowledge, emphasized the strength of the collaboration: "With their unique LiveSLR content offering, technically expert researchers, and nimble delivery model, Cytel’s team integrates perfectly with health economists’ complex workflows, allowing them to meet the changing demands for HTA-grade evidence in an evolving global pharmaceutical marketplace. We’re honored to be working with them and look forward to supporting our mutual clients.”

With growing demand for real-time, rigorous, and transparent evidence, the pairing of Cytel’s LiveSLR® platform with Nested Knowledge’s software positions Cytel at the forefront of an evolving global landscape – offering life sciences innovators an unmatched, AI-enabled solution for strategic decision-making.

About Cytel
Cytel a world leading data-science CRO, driving advancements in human health through robust analytics and innovative clinical trial software. For nearly four decades, we have set the standard in adaptive trial design, leveraging extensive data insights to inform strategy throughout every phase of drug development and commercialization. Our mission is clear: accelerate drug development, enhance success rates, and deliver better patient outcomes. With a comprehensive suite of services from innovative trial design to end-to-end biometrics and real-world evidence, our specialized, multidisciplinary team ensures optimal strategies for pre-clinical research, trial execution, market access, and reimbursement.

About Nested Knowledge
Nested Knowledge is a software company transforming how evidence synthesis is performed and consumed. Their AI-powered platform supports end-to-end workflows for systematic literature reviews, from search to visualization, and offers "living” evidence libraries that update as new data emerges.

LiveSLR® is a registered trademark of Cytel Inc. All rights reserved.



Sofie Vandevyver
Cytel
sofie.vandevyver@cytel.com

Nachrichten zu Mitsubishi Materials Corp

  • Relevant
  • Alle
  • vom Unternehmen
  • ?
Keine Nachrichten verfügbar.

Analysen zu Mitsubishi Materials Corp

  • Alle
  • Kaufen
  • Hold
  • Verkaufen
  • ?
Zu diesem Datensatz liegen uns leider keine Daten vor.
Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen

Unbekannte Renditechampions? – Daniel Riediker zu Gast im BX Morningcall mit François Bloch

Strukturierte Kredite – hohe Rendite bei geringerem Risiko? Daniel Riediker, CEO & Mitgründer von Alegra Capital, erklärt im BX Morning Call, warum CLOs (Collateralized Loan Obligations) zu den spannendsten, aber am wenigsten verstandenen Investments gehören – und wie seine Fonds Krisen wie die Finanzkrise und Covid meistern konnten.

Im aktuellen BX Morning Call sprechen François Bloch und Olivia Hähnel (BX Swiss) mit Daniel Riediker, CEO und Mitgründer von Alegra Capital, einem der führenden europäischen Experten im Bereich strukturierter Kreditverbriefungen.

Seit 2003 ist Alegra Capital auf CLOs (Collateralized Loan Obligations) spezialisiert – ein komplexes, aber oft unterschätztes Anlageinstrument mit beeindruckender Performance und klarer Strategie. Im Gespräch gewährt Daniel Riediker exklusive Einblicke in die Welt der CLOs, spricht offen über Herausforderungen während der Finanzkrise, seine Investmentphilosophie und erklärt, warum seine Fonds seit Jahren zu den leistungsstärksten Alternativen im Fixed-Income-Bereich zählen.

👉🏽 https://bxplus.ch/bx-musterportfolio/

Unbekannte Renditechampions? – Daniel Riediker zu Gast im BX Morningcall mit François Bloch

Mini-Futures auf SMI

Typ Stop-Loss Hebel Symbol
Short 12’672.04 19.68 BKYSTU
Short 12’934.82 13.50 SS4MTU
Short 13’404.86 8.81 BDGS0U
SMI-Kurs: 12’227.28 15.05.2025 17:30:33
Long 11’730.06 19.68 BQUSIU
Long 11’433.96 13.27 BH2SIU
Long 10’986.67 8.88 B38SLU
Die Produktdokumentation, d.h. der Prospekt und das Basisinformationsblatt (BIB), sowie Informationen zu Chancen und Risiken, finden Sie unter: https://keyinvest-ch.ubs.com

finanzen.net News

Datum Titel
{{ARTIKEL.NEWS.HEAD.DATUM | date : "HH:mm" }}
{{ARTIKEL.NEWS.BODY.TITEL}}